US investment bank H.C. Wainwright has reiterated its positive rating on MannKind Corporation (NASDAQ: MNKD) following the US Food and Drug Administration's (FDA) continued approval of the company's inhaled insulin product, Afrezza. The announcement, made late on Friday, has provided a modest boost to the stock, which rose around 1.2% in pre-market trading to approximately $5.40 per share.
The FDA's decision confirms that Afrezza, a rapid-acting inhaled insulin for adults with diabetes, meets the agency's safety and efficacy standards. H.C. Wainwright analysts noted that the approval removes a key regulatory overhang for the company, allowing it to focus on commercial expansion in the US diabetes market. MannKind has been working to increase physician adoption and patient access through partnerships with pharmacy benefit managers.
For UK investors, the development is a reminder of the influence of US regulatory decisions on global biotech valuations. While MannKind is not listed on the FTSE, many UK pension funds and investment trusts hold US healthcare stocks as part of diversified portfolios. The broader Nasdaq Biotechnology Index (NBI) edged up 0.3% on the day, reflecting cautious optimism across the sector.
Analysts at H.C. Wainwright highlighted that MannKind's revenue trajectory remains dependent on Afrezza's market uptake, which has historically been slow due to competition from traditional injectable insulins. However, the firm believes that the FDA's continued backing could support a gradual improvement in prescription volumes. 'The regulatory clarity is a positive step, but commercial execution remains the key variable,' one analyst commented.
In the UK, diabetes affects approximately 5.6 million people, with type 1 and type 2 patients relying on insulin therapy. While Afrezza is not currently approved by the Medicines and Healthcare products Regulatory Agency (MHRA), UK healthcare investors often track US biotech trends as leading indicators for future product launches in Europe. Any future submission to the MHRA could open a new market for MannKind, though no timeline has been announced.